NASH Target Development Service for AnxA1 Analogues

Creative Biolabs is a professional therapeutic drug development expert with extensive experience in target screening, structural characterization, functional profiling, safety evaluation, and production process optimization. We have won good reputation among our worldwide customers for successfully accomplishing numerous challenging projects in ANXA1 or its analogues for NASH treatment. We guarantee the finest results for our customers all over the world.

Introduction of AnxA1

AnxA1, also known as annexin A1 or lipocortin I, is a member of annexin protein family and is responsible for modulating the adaptive immune response in vivo. More recent studies have demonstrated that the generation of AnxA1 plays an important role in regulating anti-inflammatory of glucocorticoids against inflammatory. Glucocorticoids are a type of innate steroid hormones that closely bind to the receptor of glucocorticoid (GR), which have been considered as a key factor in anti-inflammatory in various animal models. Meanwhile, AnxA1 has been found that it can inhibit the expression of phospholipase A2 and thus blocking the production of eicosanoid and a number of leukocytes associated inflammatory reactions. Furthermore, researchers have revealed that AnxA1 is an attractive target for a wide variety of diseases caused by overreaction of immune system, such as allergies, asthma as well as certain types of autoimmune diseases. Bedsides, serial studies of AnxA1 have proved that it is a key target for treatment of nonalcoholic steatohepatitis (NASH) due to its effect on mediating the inflammation and fibrogenesis in AnxA1 knockout mice. In addition, a series of studies have shown that the expression of AnxA1 is up-regulated in a number of cancer cell lines, including lung cancer, liver cancer, melanoma, endometrial carcinoma as well as colorectal cancer (CRC).

Fig.1 Cellular events associated with the anti-inflammatory and proresolving effects of annexin A1 (AnxA1) and its mimetic N terminal peptides. (Sugimoto, 2016)

Our Platform for AnxA1 Analogues

The AnxA1 is a protein that is involved with anti-inflammatory immune response in a majority of diseases. Moreover, the research has illustrated that recombinant AnxA1 can affect the cell proliferation and cell differentiation, especially in T cells, suggesting it could be a perfect therapeutic molecule in many inflammatory diseases and certain tumors. Therefore, Creative Biolabs has established a panel of assays for discovering novel therapies targeting AnxA1 or AnxA1 analogues in a full range of diseases, such as NASH diseases, autoimmune diseases as well as various tumors. Additionally, we also provide a seamless service on the use of AnxA1 analogs for therapeutic treatment of NASH, including CR-AnxA12-50, Ac2-26, polymer-AnxA1, and ALX-FPR2 agonists. Equipped with a team of experts and state-of-art technologies, we can offer high-quality target construction and custom target screening services of AnxA1 or AnxA1 analogues for our clients to meet any requirement of the projects.

Fig.2 Hepatic AnxA1 expression in mice with NASH. (Locatelli, 2014)

Creative Biolabs is a leader in the field of disease target development and has focused on the treatment of NASH therapies for years. We have experienced experts and advanced platforms that are able to provide excellent services. If you are interested in our services, please contact us for more details.

References

1. Sugimoto, M.A.; et al. Annexin A1 and the resolution of inflammation: modulation of neutrophil recruitment, apoptosis, and clearance. J Immunol Res. 2016, 2016.
2. Locatelli, I.; et al. Endogenous annexin A1 is a novel protective determinant in nonalcoholic steatohepatitis in mice. Hepatology. 2014, 60(2): 531-544.